For a selected group of patients with hepatocellular carcinoma (HCC), liver transplantation (LT) represents the best chance of a cure. Organ shortages necessitate an efficient allocation of resources and careful prioritization on the transplantation waiting list. In this review, we aim to collate and evaluate the published evidence for using response to locoregional therapies (LRTs), measured by modified Response Evaluation Criteria in Solid Tumors (mRECIST), as a predictor of longterm survival after LT. Our aim was to assess whether response to LRTs before LT for HCC, as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) or mRECIST criteria, can help predict recurrence-free and/or longterm survival outcomes. We searched MEDLINE, Embase, and the Cochrane database. We included randomized controlled trials (RCTs), cohort, case control, and case series studies. Poster and conference abstracts were included. Studies were required to use RECIST or mRECIST criteria when assessing tumor response and were limited to LT for HCC only. A total of 15 records were included in the final systematic review: 7 published manuscripts and 8 conference abstracts. No RCTs were identified. Several included articles were conference abstracts with limited data available. No RCTs were found, and no meta-analysis was undertaken. Several retrospective cohort studies were identified that demonstrated statistically significant differences in survival and recurrence between different RECIST criteria after LT.
For a selected group of patients with hepatocellular carcinoma (HCC), liver transplantation (LT) represents the best chance of cure. Transplantation not only removes the primary lesion, it also removes the diseased liver that provides a fertile ground for the development and growth of new disease. Appropriate patient selection forms the cornerstone for any transplantation service. Mazzaferro et al. (1) reported acceptable survival results for patients with limited disease burden (a single HCC lesion <5 cm in size or 3 or fewer lesions with the largest <3 cm in size)-the Milan criteria (MC). Since then, the parameters of acceptable outcomes for transplantation for HCC have been expanded upon by various groups. (2) In the context of LT, locoregional therapies (LRTs) have been used as either a bridging strategy, to maintain a patient on a transplant waiting list, or a downstaging strategy to make a patient eligible for transplant. Many different types of LRT exist, including Abbreviations: AFP, alpha-fetoprotein; AP, any progression; BCLC, Barcelona Clinic Liver Cancer; CI, confidence interval; CR, complete response; HCC, hepatocellular carcinoma; cTNM, clinical TNM; HCV, hepatitis C virus; HR, hazard ratio; ITT, intention-to-treat; LRT, locoregional therapy; LT, liver transplantation; MC, Milan criteria; MC-IN, within Milan criteria; MC-OUT, outside Milan criteria; MELD, Model for End-Stage Liver Disease; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, odds ratio; OS, overall survival; PD, progressive disease; PEI, percutaneous ethanol injection; PR, partial response; RCT, randomized controlled trial; RECIST, Response Evaluation Criteria in Solid Tumors; RFA, radiofrequency ablation; RFS, recurrence-free survival; SBRT, stereotactic body radiation therapy; SD, stable disease; TACE, transarterial chemoembolization; UCSF, University of California, San Francisco.
transarterial chemoembolization (TACE), radiofrequency ablation (RFA) or microwave ablation, and percutaneous ethanol injections (PEIs). These therapies can also be used on their own or in combination outside of the transplant setting in patients not suitable for transplantation or resection. (3, 4) Organ shortages necessitate efficient allocation of resources and prioritization of the waiting list. Treatment on the waiting list with LRT to avoid dropout is recommended based on current evidence. (5) However, no such recommendation exists for using response to LRT as a predictor of posttransplant outcome. (6) It is possible that response to treatment is such a strong predictor of recurrence after transplant and/or wait-list dropout that it should influence both eligibility criteria for transplant and prioritization for transplant (through for instance a modification of tumor Model for EndStage Liver Disease [MELD] ). In recent years, interest has been shown on the effect that LRTs have on longterm survival after transplantation, with the view to using this information in determining a "biological selection" criteria to appropriately expand the purely size-based MC or University of California, San Francisco (UCSF) criteria. (7) However, definite recommendations remain elusive. (8) There are multiple ways of measuring tumor response; this review will look at pretransplant radiologic response as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) (9) or modified Response Evaluation Criteria in Solid Tumors (mRECIST). (10) The RECIST criteria categorize tumor response into 4 categories: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD), based on radiological investigations. The modified criteria were created specifically for HCCs to make assessing response to molecular-targeted therapies or LRTs more consistent by introducing measurement of arterial phase enhancement. Other options for response measurement include changes in pretransplant alphafetoprotein (AFP) levels (11) (12) (13) and explant tumor necrosis. (14, 15) 
Methods

ELIGIBILITY CRITERIA
We limited our search to the years 1980-2016 for the English language only. Randomized controlled trials (RCTs), cohort, case control, and case series studies were included, including conference poster and verbal presentations. Only LT for HCC was considered. LRTs including TACE, RFA, PEI, and surgical resection were considered; however, studies looking only at surgical resection before salvage transplantation were excluded. Appropriate imaging before and after LRT was required, and the response must have been reported in terms of RECIST or mRECIST. At least 3-year recurrence-free survival (RFS) or overall survival (OS) had to be reported to ensure adequate follow-up periods were used.
INFORMATION SOURCES
MEDLINE via OvidSP, Embase, and the Cochrane databases were searched. Authors of conference abstracts in the final review were contacted if possible to provide additional data.
SEARCH
A comprehensive search was undertaken on June 8, 2015 and updated in May 2016 using the following key terms and their synonyms: liver transplantation; overall, recurrence-free and disease-free survival; TACE, RFA, PEI, cryotherapy, and yttrium radioisotopes. A simplified search of HCC treatment was performed on the Cochrane database. The search strategy was formulated by all authors.
STUDY SELECTION
The search results from the 2 databases used were merged, and duplicates were removed automatically in Endnote. Studies were screened initially by title alone, followed by abstract, with duplicates that were missed by automatic matching removed manually. A full text review was performed on a short list of articles when available (ie, not a poster presentation). A final decision on full articles to include in the qualitative analysis, and conference abstracts to request further data on, was made. One author (P.D.M.) screened studies by title and abstract. Two authors (P.D.M. and C.S.) performed the full text review.
DATA COLLECTION PROCESS
Data were manually extracted into Review Manager by P.D.M. and validated by C.S. Data points to extract were agreed on by all authors. A standardized extraction form was used. A standard request for data form was sent to the authors of conference abstracts to provide further information not available in the abstract. If returned, these data were included in the review.
DATA ITEMS
We extracted the following items from each article where it was reported:
Paper characteristics: including study type, center type, LT, TACE, and analysis inclusion and exclusion criteria. Population: including sample size, baseline characteristics (eg, MELD scores, HCC etiology), and follow-up period. Interventions: types of LRT used and numbers associated with each therapy. Outcomes: hazard ratios (HRs), 5-year RFS, and 5-year OS for each RECIST criteria where reported. Other important conclusions of the study were also recorded.
SUMMARY MEASURES
The principle summary measures are 5-year RFS and OS.
SYNTHESIS OF RESULTS
Data were arranged in tabular form and qualitatively reviewed. No meta-analysis was undertaken because of a lack of RCTs and heterogeneity between studies. HRs were estimated using Peto's method. (16) This systematic review was performed according to the PRISMA guidelines. (17) 
Results
STUDY SELECTION
The search yielded a total of 4441 articles from MEDLINE and Embase. No relevant entries were found in the Cochrane database. No articles from other sources were included; 911 duplicates were identified either automatically by Endnote or manually by the authors. The remaining 3530 articles were screened initially by title, leaving 383 articles, then by abstract, leaving 66 possible articles for full text review. Of these articles, 18 were included in an initial short list. However, 3 conference abstracts were removed after authors did not respond to requests for further data. A total of 15 studies were included in the final selection-1 published prospective cohort study, (18) 6 published retrospective cohort studies, (19) (20) (21) (22) (23) (24) and 8 conference abstracts. (25) (26) (27) (28) (29) (30) (31) (32) We had access to additional data and an unpublished manuscript for 1 conference abstract. (25) The selection process is shown in Fig. 1 .
STUDY CHARACTERISTICS
Study characteristics and their patient populations are displayed in Table 1 . One prospective study (18) and 1 multicenter study (21) were found. These articles represent cohort analyses of a total of 1885 patients who received both LRT and a LT. Age and sex distribution of the populations was similar for all studies (mean/median age 56.9-65 years, percentage male 72.8%-85.3% where reported). All articles included multiple etiologies for HCC except Sogawa et al., (27) which included only HCV patients. Maximum study duration was 19 years. (20) Follow-up periods ranged from a median of 24.3 months (19) to 6.5 years. (20) Two studies were reported as intention-to-treat (ITT) for all patients listed for LT. (18, 19) Only 1 published manuscript explicitly stated the inclusion of living donor LTs in their cohort. (24) Two published manuscripts had study periods that were entirely within the MELD era (19, 23) ; others spanned before and after MELD. Differences were noted in the inclusion and exclusion criteria for the study, LRT, and listing for LT. For example, the inclusion criteria for pre-LT TACE for Otto et al. was age < 71 years, cirrhosis, 2 cycles of TACE, HCC < 10 cm regardless of number of lesions, and absence of factors contraindicating orthotopic LT; in comparison, Shuster et al. used any single tumor > 5 cm in maximal diameter, 3 or more nodules > 3 cm, Child-Pugh class A and B, normal left ventricular ejection fraction (55%-80%), and Eastern Cooperative Oncology Group performance status 0-1. (22, 23) Sample sizes of patients who received both LTs and LRTs range from 20 to 422. LRTs also varied, with TACE as the most common treatment overall. Eight studies used only TACE; all studies that included multiple interventions had TACE as 1 of those. The reported patient and tumor characteristics, for example, tumor stage or number/size, were also variable.
RESULTS OF INDIVIDUAL STUDIES
Numerical results of each study are given in Table 2 . LRTs included TACE, RFA, PEI, LR, radiotherapy, and various combinations of these.
Overall Survival and Recurrence
Several articles reported a statistically significant improvement in both RFS and OS at 5 years. Lai et al. (21) present the largest patient cohort and analyze the effect both AFP changes and mRECIST have. This article showed that PD was associated with HRs of 3.5 (P < 0.001) and 1.6 (P < 0.04) compared with CR, PR, or SD for RFS and OS, respectively. Sandroussi et al. (25) showed survival rates stratified by criteria (CR 5 84%/84%; PD 5 41%/52%; P 5 0.003/0.04; RFS and OS, respectively). Jianyong et al. (32) showed an improvement in the group with a CR or PR compared with SD or PD (75.0% versus 54.9%, P 5 0.02 for OS, RFS data not available, abstract only). Additionally, Lai et al. have shown that AFP can be used as a pretransplant marker for biological selection by demonstrating that a gradient of >15 ng/mL/month is significantly associated with reduced RFS and OS (HR, (18) and Shuster et al. (23) both report that patients who had CR or PR had significantly longer OS compared with SD or PD (CR 5 85.1% versus SD1PD 5 51.4%, P 5 0.02; CR1PR 5 89.9% versus SD1PD 5 34.3%, P 5 0.02, respectively). Millonig et al. also did an ITT analysis on all patients listed for transplant who received LRT. This shows a greater statistical impact on 5-year OS of 85.7% for CR compared with 19.3% for SD or PD (P < 0.01). Despite these results, they conclude that tumor stage and waiting time are the most important factors influencing outcome after LT. Additionally, Shuster et al. (23) showed that response measured according to the RECIST criteria was superior to the European Association for the Study of the Liver criteria at predicting longterm posttransplant survival (P 5 0.005).
Several authors (19, 20, 22, 24, 26, 30, 31) reported RFS data only. Both Cucchetti et al. (19) and De Simone et al. (26) have found that the group with CR had a significant decrease in the recurrence risk compared with SD, PR, or PD, but no effect on survival (recurrence rate, 5.5% versus 19.4% P 5 0.02; RFS, 100% versus 86.8%, P 5 0.006, respectively). Both of these cohorts included patients initially satisfying MC. Cucchetti et al. also did an ITT analysis and showed that 5-year OS was significantly impacted by response criteria-patients with CR having a survival of 66.4% compared with PR, SD, or PD with 45.0% (P 5 0.001). This statistical significance was not found when analyzing only the LT cohort (P 5 0.10). Furthermore, they demonstrated that CR reduced the probability of drop-off after 12 months on the waiting list compared with other RECIST criteria (9.4% versus 28.9%; P < 0.001).
Seehofer et al. (20) found that PD was significantly associated with an increased recurrence rate, but only for patients outside of MC at listing (P 5 0.047). On multivariate analysis of all patients in their study (ie, patients who received TACE and those who did not), they found that changes according to the RECIST criteria were associated with a significant increase in recurrence rate (HR, 2.12; P 5 0.02), but not associated with OS (HR, 1.04; P 5 0.88). Furthermore, Seehofer et al. (20) found no statistically significant impact on waiting time to LT, recurrence, or survival between those who received TACE and those who did not. Otto et al. (22) have shown that there was a significant reduction in RFS for the PD group compared with SD or PR (RFS, 22% versus 88%; P < 0.001, respectively). This article also defines an "any progression" (AP) category-any increase in size and/or the appearance of new measurable lesions-which was associated with a more pronounced difference between those inside AP than those outside (21% versus 92%, respectively; P < 0.001). Kim et al. (24) demonstrated that both 5-year RFS and recurrence rate were significantly better for patients with a CR or PR compared with SD or PD (recurrence rate, 5.3% versus 17.6%, respectively; P 5 0.01). Nicolini et al. (31) and Na et al. (30) both described SD or PD as independent risk factors of recurrence (P 5 0.03 and P 5 0.04, respectively, both conference abstracts).
In contrast to the other groups, Sogawa et al., (27) Mannina et al., (28) and Han et al. (29) did not identify a significant effect on OS or RFS in terms of response to locoregional treatment as measured by RECIST (all 3 conference abstracts).
Milan Criteria
Several articles made observations about the use of RECIST and the MC. (18, (20) (21) (22) 25) Millonig et al. (18) demonstrated that those within Milan criteria (MC-IN) who had SD or PD on the waiting list had significantly worse OS compared with CR (1-year OS, 37.5% versus 89.2%; P 5 0.04). However, this did not apply to disease that extended outside Milan criteria (MC-OUT; P 5 0.39 for UCSF). MC-IN patients were also less likely to be removed from the waiting list due to progression compared with UCSF, however, not statistically significantly so (P 5 0.08). Sandroussi et al. (25) have shown similar results, concluding that MC-IN patients with CR, PR, or SD had significantly improved RFS over PD (91% versus 47%, P < 0.001, respectively). There was no significant difference for MC-OUT patients. Lai et al. (21) have shown that patients who are initially MC-OUT but do not have PD or AFP slope > 15 ng/mL/month after LRT can achieve a very good post-LT RFS of 87%, significantly better than MC-IN patients who had 1 or both of the above (P 5 0.01). Furthermore, they conclude that initially MC-OUT patients with a poor response after LRT should have their position on the transplant waiting list re-evaluated as they have significantly worse posttransplant survival (HR, 3; P 5 0.02). MC-IN patients experiencing progression after LRT have an increased risk of tumor recurrence and death after LT in comparison with patients who have a CR (recurrence/death HR, 2.2/2 versus 0.6/0.5; P 5 0.02/0.02). Otto et al. (22) have shown that for patients who were MC-IN after TACE there was a significantly increased 5-year RFS compared with those patients who were MC-OUT after TACE patients (88% versus 55%; P < 0.001). However, there was no significant difference for MC-IN or MC-OUT at time of listing (81% versus 77%; P 5 0.58), indicating that the tumor biology as predicted by the response to TACE had a significant effect on posttransplant survival. Moreover, PD was a stronger predictor of 5-year recurrence than MC after TACE. In contrast, Seehofer et al. (20) showed that MC-OUT patients with PD had a significantly impacted risk of recurrence compared with CR, PR, or SD (HR, 3.2; P 5 0.01), a split that lost significance for MC-IN patients (HR, 1.34; P 5 0.53).
Discussion
SUMMARY OF EVIDENCE
This systematic review shows that there are demonstrable differences in survival when patients are stratified by RECIST/mRECIST criteria. However, data presented are heterogeneous. Patient selection criteria varied between each study, as did therapeutic regimes, ranging from TACE only to multiple treatment modalities. Inclusion criteria to the study, LRT, and listing for LT also varied between each study, which is likely a significant contributor to heterogeneity. The effect that tumor response had on longterm overall and disease-free survival varied, especially when comparing which differential of RECIST categories led to statistically significant results. Several articles reviewed were conference abstracts, limiting the applicability of the published statistics because of limitations on the information provided about patient selection, tumor characteristics, treatment protocol, and outcome data.
Despite many of the selected articles identifying a significant improvement in both RFS and OS for those who have a response to locoregional treatment, firm conclusions are difficult to draw. There is heterogeneity between RECIST criteria stratification and what significantly predicts survival. For example, out of the 5 published manuscripts that reported RFS only, 1 found CR improved it compared with the other categories, and 3 found that PD reduced it. We demonstrate the published manuscripts that showed PD increased the risk of recurrence after transplant with a Forest plot of HRs, without meta-analysis, in Fig. 2 . When reviewing published manuscripts that used only TACE, (18, 20, (22) (23) (24) 3 out of 5 of these found statistically significant results when comparing CR or PR to SD or PD for either OS or RFS, again showing heterogeneity in results even with the same LRT.
Important observations about longterm outcomes when combining RECIST with the MC have also been made. However, as with recurrence and survival, the data are heterogeneous. These results have identified the importance of tumor biology as a selection criterion for LT, and in the future, the response to LRT according to the RECIST criteria may be used as a surrogate biological selection marker and hence inform decisions about patient suitability for LT. It is clear from many of the included studies that improvements can be made upon MC (and by extension, UCSF), with multiple articles concluding that RECIST predicted longterm outcomes better than criteria at the time of listing or that combinations of the criteria and progression may help exclude patients who have a high likelihood of a poor posttransplant outcome. If modifications to criteria are to be considered, further controlled studies that can be repeated in different geographical regions are required that also consider the outcome of patients not enrolled on a LT waiting list at all.
Other pretransplant factors are also under investigation to determine if they can be used as reliable markers for tumor biology, including AFP level and gradient, (33, 34) and neutrophil-to-lymphocyte ratio. (35, 36) 
LIMITATIONS
The main limitation of this systematic review is that no RCTs were found; we identified only cohort studies. Many of these studies were conference abstracts only. No meta-analysis could be performed. There was much heterogeneity between published data in terms of LRT regimens, selection criteria to LRT and LT, and subgroup analysis to reach statistical significance. Ideally, only mRECIST would have been an inclusion criterion. However, this would have resulted in many articles with important results being excluded. Only 2 studies included ITT analyses for all patients who received LRT when listed for transplantation, making conclusions about the overall impact response to therapy difficult to draw. Many studies had progression on the waiting list as a criterion for exclusion from LT. This means any benefit seen from transplanting only patients with response to treatment is likely to be much greater on an intention basis than has been demonstrated by these articles, as it was in the studies that performed an ITT analysis.
In conclusion, appropriate allocation of finite deceased donor organs is fundamental to transplantation programs. Current allocation policies using only tumor size and number may be excluding patients outside these criteria who have biologically favorable disease and would achieve equivalent survival outcomes to those within such criteria. This systematic review seeks to look at 1 possible pretransplant measurement of tumor biology-radiological response as measured by RECIST or mRECIST. All the data on this topic are derived from uncontrolled or nonrandomized comparative studies, and heterogeneity was noted between patient selection, treatment, and results. More prospective trials are clearly required. Also beneficial to the future study of this topic would be increased standardization for LRTs and consistent use of mRECIST rather than RECIST. This may lead to meta-analysis being possible even without RCTs. On the basis of current evidence, no definitive conclusions can be drawn. However, several articles did identify statistically significant results, and we believe this topic is worthy of further investigation. In the future, patients with CR or PD may be re-evaluated for either inclusion or exclusion from a LT waiting list, respectively.
